Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $20

Author: Benzinga Newsdesk | March 01, 2024 09:43am
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and raises the price target from $12 to $20.

Posted In: ORIC